Last $278.15 USD
Change Today +1.77 / 0.64%
Volume 1.1K
RHHVF On Other Exchanges
SIX Swiss Ex
SIX Swiss Ex
As of 3:00 PM 12/22/14 All times are local (Market data is delayed by at least 15 minutes).

roche holding ag-genusschein (RHHVF) Snapshot

Previous Close
Day High
Day Low
52 Week High
02/24/14 - $340.18
52 Week Low
01/27/14 - $265.90
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

roche holding ag-genusschein (RHHVF) Details

Roche Holding AG operates in the pharmaceuticals and diagnostics businesses in Switzerland, European Union, and internationally. It discovers, develops, and provides diagnostic and therapeutic products and services that enable patients and healthcare professionals in the detection, prevention, diagnosis, treatment, and treatment monitoring of diseases. The company provides pharmaceutical products for various therapeutic areas comprising oncology, virology, inflammation, metabolic disorders, and central nervous system. In addition, it offers a portfolio of diagnostics products, such as blood glucose meters for diabetes patients; point-of-care testing devices for use in doctors’ offices; high-throughput analyzers for hospitals and commercial diagnostic laboratories; and start-of-the-art instruments and reagents for life science research. The company has a collaboration agreement with Astrazeneca Plc to develop a plasma-based companion diagnostic test to support AZD9291, a drug candidate for treating non-small-cell lung cancer; and a collaboration agreement with AmorChem L.P. to discover novel small molecule disease-modifying therapy for the treatment of myotonic muscular dystrophy 1 or Steinert's disease. Roche Holding AG was founded in 1896 and is headquartered in Basel, Switzerland.

85,080 Employees
Last Reported Date: 01/30/14
Founded in 1896

roche holding ag-genusschein (RHHVF) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: SFr.5.1M
Compensation as of Fiscal Year 2013.

roche holding ag-genusschein (RHHVF) Key Developments

Roche Launches Next-Generation Viral Load Testing Assays for New Molecular Diagnostic Platforms in Markets Accepting the CE Mark

Roche announced the commercial availability of the cobas HIV1 and cobas HCV assays for use on the cobas 6800/8800 Systems--expanding the menu on the newest molecular diagnostic platforms from Roche with next generation viral load monitoring assays. The new assays offer the high performance that clinicians depend on to manage the treatment of patients infected with Human Immunodeficiency Virus (HIV1) or Hepatitis C (HCV). The assays launched will be followed in the coming months by the cobas CMV and cobas HBV assays, which will complete the primary portfolio of viral load monitoring assays for the cobas 6800/8800 Systems. This viral load portfolio on the cobas 6800/8800 Systems will provide laboratories with improved productivity and the ability to deliver results for rapid clinical decisions. The cobas HIV1 and HCV assays and the cobas 6800/8800 Systems are commercially available in markets that recognize CEMark and are not currently available in the United States.

TTPH Reportedly Explores Options For Sale

Tetraphase Pharmaceuticals, Inc. (NasdaqGS:TTPH) is exploring a sale after attracting interest from potential buyers, people familiar with the matter said. TTPH is working with advisers to explore its options, the people said, asking not to be identified because the deliberations are private. TTPH may attract interest from bidders including Actelion Ltd. (SWX:ATLN) and Roche Holding AG (SWX:ROG), the people said. A spokesman for Tetraphase declined to comment. Representatives for Actelion and Roche couldn’t immediately be reached to comment outside of normal business hours.

Roche Holding AG and Inovio Pharmaceuticals, Inc. Terminate Prostate Cancer Collaboration

Roche Holding AG and Inovio Pharmaceuticals, Inc. have announced the termination of their prostate cancer alliance that involved a research collaboration and joint development of the US company's DNA immunotherapy targeting the disease, INO-5150. Roche will therefore return the rights to INO-5150 to Inovio, with the US firm intending to continue the advance of the investigational drug to a Phase I trial in the first half of 2015. The termination of the prostate cancer collaboration between the companies would potentially come as a setback to Inovio, considering that the advancing of INO-5150 to a Phase I trial would have triggered a milestone payment from Roche. The companies have nevertheless stated that they intended to continue their collaboration on jointly developing Inovio's DNA immunotherapy INO-1800 to potentially treat hepatitis B virus. In pre-clinical trials INO-1800 was shown to have generated strong T-cell and antibody responses, consequently eliminating the targeted liver cells in mice. The companies are looking to advance the investigational hepatitis B vaccine to a Phase I trial in 2015.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RHHVF:US $278.15 USD +1.77

RHHVF Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AbbVie Inc $67.25 USD -0.46
Bayer AG €115.51 EUR +1.50
General Electric Co $25.67 USD +0.05
Gilead Sciences Inc $94.18 USD -14.27
Merck & Co Inc $58.79 USD -0.79
View Industry Companies

Industry Analysis


Industry Average

Valuation RHHVF Industry Range
Price/Earnings 19.6x
Price/Sales 4.2x
Price/Book 11.9x
Price/Cash Flow 15.9x
TEV/Sales 2.9x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ROCHE HOLDING AG-GENUSSCHEIN, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at